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Abstract
Background: Long non-coding RNAs (lncRNAs) have emerged as critical regulators of tumor progression. However,
the role and molecular mechanism of lncRNA XIST in gastric cancer is still unknown.
Methods: Real-time PCR analysis was performed to measure the expression levels of lncRNA XIST in gastric cancer
tissues and cell lines, the correlation between lncRNA XIST expression and clinicopathological characteristics and
prognosis was analyzed in gastric cancer patients. The biological function of lncRNA XIST on gastric cancer cells
were determined both in vitro and in vivo. The regulating relationship between lncRNA XIST and miR-101 was
investigated in gastric cancer cells.
Results: lncRNA XIST was significantly up-regulated in gastric cancer tissues and cell lines. Overexpression of
lncRNA XIST was markedly associated with larger tumor size, lymph node invasion, distant metastasis and TNM
stage in gastric cancer patients. Functionally, knockdown of lncRNA XIST exerted tumor-suppressive effects by
inhibiting cell proliferation, migration and invasion in vitro and tumor growth and metastasis in vivo. Furthermore,
an inverse relationship between lncRNA XIST and miR-101 was found. Polycomb group protein enhancer of zeste
homolog 2 (EZH2), a direct target of miR-101, could mediated the biological effects that lncRNA XIST exerted.
Conclusions: lncRNA XIST is up-regulated and is associated with aggressive tumor phenotypes and patient survival
in gastric cancer, and the newly identified lncRNA XIST/miR-101/EZH2 axis could be a potential biomarkers or
therapeutic targets for gastric cancer patients.
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Background
Gastric cancer is one of the most common malignant
diseases and the second leading cause of cancer-related
mortalities worldwide [1]. Despite great developments in
the diagnosis and therapy of this disease in the past
decades, the overall survival rate of gastric cancer
patients is still unsatisfied. In most cases, gastric cancer
is diagnosed at advanced stage which is characterized
with malignant proliferation, extensive invasion and
distant metastasis. Traditionally, the TNM stage was
used as an indicator to predict prognosis of patients,
recent studies have proved that the criteria alone is not
sufficient for estimating prognosis [2, 3]. Therefore,
there is an urgent need to identify novel biomarkers that
can predict patient survival and be used as therapeutic
targets. Previously, we have found that L1cam plays a
critical role in the progression of gastric cancer and
Paxillin is a prognostic indicator of gastric cancer
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patients [4, 5]. Recent years, evidences have indicated
that long non-coding RNAs (lncRNAs) also act as
modulators in the progression of gastric cancer and
might serve as novel therapeutic targets [6].
As the development of the human genome project, it
has been recognized that the vast majority of mamma-
lian genome are transcribed to produce non-coding
RNAs (ncRNAs) [7]. Among which are a new group of
RNAs, known as long non-coding RNAs (lncRNAs).
lncRNAs are a class of transcripts which are greater than
200 nt in size and lack significant protein-coding cap-
acity. lncRNAs are functionally diverse which can act as
guides, decoys, scaffolds and tethers of other biological
molecules [8]. Recent studies indicated that lncRNAs
could competitively suppress miRNAs by acting as mo-
lecular sponges [9]. For instance, it has been found that
lincRNA-ROR acted as a molecular sponge for miR-145
in triple-negative breast cancer [10]. lncRNA NEAT1
promotes laryngeal squamous cell cancer through regulat-
ing miR-107/CDK6 pathway [11]. Increasing evidences
demonstrated that lncRNAs are critical regulators of
multiple biological processes, including cell growth,
cell apoptosis, cell differentiation, cell invasion and
stem cell pluripotency [12–16].
The lncRNA XIST (X-inactive specific transcript) is a
product of the XIST gene and the master regulator of X
inactivation in mammals [17]. More and more studies
indicated that lncRNA XIST plays critical role in cell
proliferation, differentiation, and genome maintenance.
It was found that lncRNA XIST is dysregulated in differ-
ent cancers. For instance, dysregulation of lncRNA XIST
may leads to alterlation of gene expression and instabil-
ity of heterochromatin [18]. lncRNA XIST was essential
for long term survival of hematopoietic stem cells [19].
A recent study demonstrated that knockdown of lncRNA
XIST exerted tumor-suppressive effects in human glioblast-
oma stem cells through up-regulating miR-152 [20]. How-
ever, the expression and biological function of lncRNA
XIST in gastric cancer is unclear.
Polycomb group protein enhancer of zeste homolog 2
(EZH2) is a methyltransferase and the core catalytic elem-
ent of polycomb repressive complex 2, which plays a crit-
ical role in the regulation of cell proliferation, migration,
invasion, tumorigenesis and metastasis [21, 22]. EZH2 has
been found to be involved in multiple tumors, including
gastric cancer [23–25]. Mastukawa and his colleagues
were the first to report the role of EZH2 and its prognos-
tic significance in gastric cancer [24]. More recently, it has
been shown that up-regulation of EZH2 contributes to
gastric cancer invasion and metastasis [26, 27].
In this study, we found that lncRNA XIST expression
was significantly up-regulated in gastric cancer tissues
and cell lines and affected clinicopathological character-
istics and prognosis in gastric cancer patients. Moreover,
knockdown of lncRNA XIST could inhibit gastric cancer
cell proliferation and invasion in vitro as well as tumori-
genesis and metastasis in vivo. Based on a bioinformatic
analysis, we found lncRNA XIST could act as a molecu-
lar sponge of miR-101. Furthermore, knockdown of
lncRNA XIST exerts its tumor-suppressive effect though
down-regulating the expression of EZH2 via miR-101.
Our study provides the first evidence of the regulatory
mechanisms of the newly identified lncRNA XIST/
miR-101/EZH2 axis in carcinogenesis and metastasis,
which may shed light on their targeted applications in
cancer therapies.
Methods
Human tissue specimens and cell culture
Fresh-frozen cancer tissues and paired normal gastric
epithelial tissues were obtained from 106 patients
who undergoing surgery at the Sun Yat-sen Univer-
sity Cancer Center from 2008 to 2010. The study
was approved by the ethics committee of the Sun
Yat-sen University Cancer Center and informed con-
sent was obtained from all patients. All the patients did
not receive any treatment before the operation. Each
patient was followed up regularly every 3 months after
surgery. The clinicopathological characteristics including
age, gender, tumor size, differentiation, lymph node in-
vasion, peritoneum dissemination, distant metastasis
and TNM stage were recorded. Overall survival was
defined as the time from the date of surgery to the date
of death or last contact.
Human embryonic kidney (HEK) 293 T cells, hu-
man gastric cancer cell lines (SGC7901, HGC27,
BGC823, MKN45, MKN28, and AGS) and the normal
gastric epithelial cell line GES-1 were obtained from
either the type Culture Collection of Chinese Acad-
emy of Sciences (Shanghai, China) or the American
Type Culture Collection. These cells were cultured
and stored according to the provider’s instructions.
Cells were routinely authenticated every 6 months
(last examined in January 2016) by cell morphology
monitoring, growth curve analysis and testing for
mycoplasma (R&D Systems’ new MycoProbe Myco-
plasma Detection Kit).
RNA extraction and real-time PCR analysis
Total RNA was extracted from tissue samples and cells
using Trizol reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s protocol. High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster
City, CA) was used for lncRNA XIST and EZH2 reverse
transcription. Quantitative real-tme PCR was performed
using TaqMan Universal Master Mix II, and GAPDH
was used as the internal control. The following primers
were used for the quantitative PCR:










For the measurement of miR-101, the All-in-One™
miRNA qRT-PCR Detection Kit (GeneCopoeia) was
used according to the manufacturer’s instructions; U6
small RNA was used as the reference. Real-time PCR
was performed with the Bio-Rad CFX96 qPCR system,
and fold changes were determined using the relative
quantification 2-△△CT method.
Lentivirus production and infection
Short hairpin RNA (shRNA) directed against human
lncRNA XIST or scrambled oligonucleotides were li-
gated into the LV-3 (pGLVH1/GFP + Puro) vector
(GenePharma, Shanghai, China). The HEK293 cells
were cotransfected with Lenti-Pac HIV Expression
Packaging Mix and the lentiviral vectors (or the control
lentivirus vectors) using Lipofectamine 2000 (Life Tech-
nologies Corporation, Carlsbad, CA, USA). After 48 h,
lentiviral particles in the supernatant were harvested
and filtered by centrifugation at 500 g for 10 min. The
SGC7901 and AGS cells were then transfected with
Lentivirus or control virus (NC). In order to select the
stably transfected cells, the cells were treated with
puromycin (2 μg/ml) for 2 weeks. GFP-positive cells
were picked as sh-XIST and sh-NC, and then used for
subsequent assays.
Cell transfections
Cell transfections were performed using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) according to the
provider’s instructions. The hsa-miR-101 mimic, has-miR-
101 inhibitor and negative control (NC) oligonucleotides
were obtained from Ribobio (Guangzhou, China). To
restore EZH2 expression, the SGC7901 cells were contra-
nsfected with has-miR-101 minics and a pcDNA3.1-EZH2
plasmid, which contained the coding sequences but lacked
the 3′-UTR of EZH2. The cells were plated in a 6-well
plate the day before transfection. The cells were trans-
fected with a final concentration of 50 nM and collected
for assays after 48 h.
Cell proliferation assays
Cell proliferation ability was determined by performing
CCK-8 assay and the colony formation assay. For CCK-8
assay, cells were seeded into a 96-well plate and cultured
at 37 °C. Each well was added with 10 μl CCK-8
solution. Then, plates were incubated at 37 °C for 2 h.
Finally, the spectrophotometric absorbance at 570 nm
was measured for each sample. All the experiments were
repeated 3 times in triplicate and the mean was calcu-
lated. For the colony formation assay, 2000 cells were
placed in a six-well plate and cultured with RPMI 1640
medium (GIBCO) containing 10 % FBS for 2 weeks.
Colonies were fixed with methanol and stained with
0.1 % crystal violet (1 mg/ml).
In vitro invasion and migration assay
The cell invasive and migratory potential was evaluated
using transwell and wound healing assays, respectively.
The cell invasive potential was determined using trans-
well assay. Briefly, the cells were suspended in serum-
free medium and seeded in the top chamber (8-μm pore;
BD Biosciences) of the inserts. 500 μl of FBS was added
to the lower chamber as the chemoattractant. 22 h later,
the non-migrated cells on the top surface were swabbed
off gently, and the cells invaded to the lower compartment
were fixed with methanol, and stained with 0.1 % crystal
violet. The number of invaded cells was calculated by
counting five random views under the microscope. The
experiment was performed in triplicate and repeated for
three times. For wound healing assay, the cells were
seeded in 6-well plates, and an artificial wound was
created using a 200-μl pipette tube. The wound closure
was observed after 36 h and imaged under a microscope.
We measured the fraction of cell coverage across the line
for the migration rate.
In vivo tumorigenesis and metastasis assays
All the animal experiments were performed according to
the National Institutes of Health animal use guidelines on
the use of experimental animals. Female BABL/c athymic
nude mice (4 to 5 weeks old) were obtained from the Ani-
mal Center of Guangdong province (Guangzhou, China).
To evaluate the in vivo tumorigenesis effect of lncRNA
XIST, the SGC7901/sh-NC and SGC7901/sh-XIST cells
(1 × 106cells/mouse) were injected subcutaneously into
the flanks of two groups of nude mice (ten for each cell
group). Tumor size was measured every 4 days and tumor
volume was estimated. After 5 weeks, the mice were killed
and the tumors were dissected out. To investigate the ef-
fect of lncRNA XIST on tumor metastasis, the SGC7901/
sh-NC and SGC7901/sh-XIST cells (2 × 106cells/mouse)
were injected into the tail vein of two groups of nude mice
(ten for each cell group). Six weeks post injection, the
mice were killed and the livers were removed and
paraffin embedded. Consecutive sections (4 μm) were
made and stained with haematoxylin-eosin. The micro-
metastases in the livers were examined and counted
under a dissecting microscope.
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Reporter vector construction and luciferase reporter assay
We used the bioinformatics databases (Starbase v2.0, miR-
code and RNAhybrid) to search for potential microRNAs
that can bind to lncRNA XIST. The fragment from
lncRNA XIST containing the predicted miR-101 binding
site was amplified by PCR and cloned into a pmirGLO
Dual-luciferase Target Expression Vector (Promega, Madi-
son, WI, USA) to form the reporter vector XIST-wild-type
(pmirGLO-XIST-Wt). To test the binding specificity, the
corresponding mutant was created by mutating the miR-
101 seed region binding site (seed sequence binding
fragment 5′-GCACTG-3′ changed to 5′-AAGTGA-3′),
which were named as pmirGLO-XIST-Mt. HEK 293 T
cells were co-transfected with the pmirGLO vector with
either wild type fragments or mutation fragments and
indicated miRNAs using Lipofectamine 2000. Luciferase
reporter assay was performed using the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI, USA)
48 h later, the firefly luciferase activity was measured
and normalized by renilla luciferase activity. To con-
firm the direct regulating relationship between miR-101
and EZH2, the full-length 3′-UTR of the EZH2 mRNA
and a mutant variant were amplified by PCR and cloned
into the XbaI site of a pGL3-basic vector (Promega) and
termed EZH2-3′UTR and EZH2-mt-3′UTR, respectively.
The miR-101 expression plasmid (pcDNA-miR-101)
was generated using synthetic oligonucleotides and the
pcDNA6.2-GW/EmGFP vector. Cells were cultured in
a six-well plate and then transfected with the pcDNAmiR-
101 or the negative control (NC) (750 ng/well), the pGL3
reporter vector (250 ng/well) and the pRL-TK luciferase
reporters (25 ng/well) using Lipofectamine 2000 (Invitro-
gen). Luciferase activity levels were measured using the
Dual-Luciferase Reporter Assay Kit (Promega) following
the manufacturer’s instructions.
Western blot analyses
Total proteins were extracted from tissues or cells and
separated using SDS-PAGE gels. Antibodies for EZH2, E-
cadherin, α-catenin, Vimentin and Fibronectin were pur-
chased from Cell Signaling Technology, and an anti-
GAPDH antibody (1:2000; Santa Cruz Biotechnology, USA)
was used as a loading control. The procedure of Western
blot analysis was performed as previously described [4].
Immunohistochemistry (IHC) analysis
The paraffin-embedded tissue blocks were cut into 4 μm
slides. Rabbit mmp-9 antibody and rabbit Ki-67 antibody
purchased for Cell Signaling Technology. IHC analysis was
performed according to a previously described method [4].
Statistical analyses
Statistical analyses were performed using the SPSS soft-
ware package (version 16.0, SPSS Inc.) or GraphPad
Prism 5.0. Survival curves were generated using the
Kaplan-Meier method and assessed using the log-rank
test. The Cox proportional hazard regression model
was performed to identify independent prognostic fac-
tors. P < 0.05 was considered to be statistically significant.
Results
lncRNA XIST expression is up-regulated in gastric cancer
tissues and cell lines
To determine whether lncRNA XIST is associated with
gastric cancer development, we first measured the ex-
pression level of lncRNA XIST in gastric cancer tissues.
The results showed that lncRNA XIST expression was
significantly increased in gastric cancer tissues as com-
pared with adjacent normal tissues (Fig. 1a, P < 0.001).
Higher lncRNA XIST expression was observed in tissues
with distant metastasis than tissues without distant me-
tastasis (Fig. 1b, P = 0.001). In addition, the lncRNA
XIST expression level was markedly correlated with the
TNM stage of gastric cancer patients (Fig. 1c, *P < 0.05,
**P < 0.001). lncRNA XIST level was then determined in
gastric cancer cell lines by real-time PCR analysis.
lncRNA XIST level was significantly higher in gastric
cancer cell lines (SGC7901, HGC27, BGC823, MKN45,
MKN28, AGS) than that of normal gastric epithelial cell
GES-1 (*P < 0.05, **P < 0.001, Fig. 2a). These results indi-
cated that increased lncRNA XIST expression might be
critical involved in gastric cancer progression.
lncRNA XIST level is associated with aggressive tumor
phenotypes and adverse prognosis in gastric cancer
patients
To investigate the clinicopathological role of lncRNA
XIST in gastric cancer, The median level of lncRNA
XIST expression (4.32) was used as a cutoff value to
divide all 106 patients into two groups. Gastric cancer
patients who express lncRNA XIST at levels higher than
the cutoff value were assigned to the high expression
group (n = 54, lncRNA XIST expression level ≥ cutoff
point), and those with expression lower than the cutoff
value were assigned to the low expression group (n = 52,
lncRNA XIST expression level < cutoff point). The
relationship between lncRNA XIST expression level
and clinicopathological parameters was summarized in
Table 1. High lncRNA XIST expression was significantly
associated with larger tumor size (P = 0.023), lymph node
invasion (P = 0.013), distant metastasis (P = 0.011) and
TNM stage (P = 0.016). However, no correlation was
observed between lncRNA XIST expression level and age,
gender, peritoneum dissemination and differentiation. In
addition, Kaplan-Meier analysis demonstrated that pa-
tients with high lncRNA XIST expression tended to have
worse overall survival than patients with low lncRNA
XIST expression (P = 0.002, Fig. 1d). Moreover, to evaluate
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whether the expression of lncRNA XIST was an independ-
ent prognostic factor for gastric cancer, univariate and
multivariate analyses were performed. Univariate analysis
demonstrated that distant metastasis (P = 0.018), TNM
stage (P = 0.027) and XIST expression level (P = 0.002) were
significantly associated with overall survival of gastric can-
cer patients (Table 2). However, multivariate analysis using
the Cox proportional hazards model for all variables that
were significant in the univariate analysis showed that only
distant metastasis (P = 0.033) and lncRNA XIST expression
level (P = 0.020) were independent prognostic factors for
patients with gastric cancer (Table 2).
Knockdown of lncRNA XIST inhibits cell proliferation,
migration and invasion in vitro
The significant increased expression of lncRNA XIST in
gastric cancer tissues prompted us to investigate its
biological role in gastric cancer cells. Due to the long se-
quence of lncRNA XIST, we knockdown the expression
of lncRNA XIST in gastric cancer cells. Real-time PCR
was performed to confirm the successful knockdown of
lncRNA XIST in gastric cancer cells (*P < 0.05, Fig. 2b).
CCK-8 assay indicated that knockdown of lncRNA XIST
significantly inhibited cell proliferation in SGC7901 and
AGS cells. (*P < 0.05, Fig. 2c and d). Colony formation
assay showed cell transfected with si-XIST formed sifni-
ficantly less clonies than those transfected with si-NC
(*P < 0.05, Fig. 2e). Moreover, transwell and wound heal-
ing assays demonstrated that the cell invasion and
migration was markedly suppressed in gastric cancer
cells transfected with si-XIST as compared with cells
transfected with si-NC (*P < 0.05, Fig. 2f and g). Besides,
we did western blot to test whether XIST can affect
epithelial-mesenchymal transition (EMT) in gastric can-
cer cells. To our interest, knockdown of XIST increased
the level of epithelial markers such as E-cadherin, α-
catenin while reduced the level of mesenchymal markers
such as Vimentin and Fibronectin (Fig. 2h). These data
Fig. 1 lncRNA XIST is significantly up-regulated in gastric cancer tissues and cell lines. a Relative expression level of lncRNA XIST in gastric cancer
tissues (n = 106) and adjacent normal tissues, lncRNA XIST expression was significantly higher in gastric cancer tissues as compared with adjacent
normal tissues (n = 106) (P < 0.001). b Relative expression level of lncRNA XIST in gastric cancer tissues with (n = 28) and without distant metastasis,
lncRNA XIST expression was lower in tissues without distant metastasis compared with tissues with distant metastasis (n = 78) (P = 0.001).
c Relative expression level of lncRNA XIST in different clinical stage (*P < 0.05, **P < 0.001). d Kaplan-Meier curve of overall-survival in
gastric cancer patients with high lncRNA XIST level (n = 54) and low lncRNA XIST level (n = 52), the overall survival time was shorter in
patients with high lncRNA XIST than those with low lncRNA XIST (P = 0.002)
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demonstrated that knockdown of lncRNA XIST could
inhibit gastric cancer proliferation and invasion in vitro.
Knockdown of lncRNA XIST inhibit tumor growth and
metastasis in vivo
To explore whether knockdown of lncRNA XIST affects
tumor growth and metastasis in vivo. We constructed
two stable cell lines by using the lentivirus vector to
mediate the knockdown of lncRNA XIST in SGC7901
cells; the resulting cells were designated as SGC7901/sh-
XIST and SGC7901/sh-NC cells respectively (Fig. 3a
and b). To investigate the in vivo effect of lncRNA
XIST knockdown on gastric cancer tumor growth, cells
(SGC7901/sh-XIST and SGC7901/sh-NC) were sub-
cutaneously injected into the flank of nude mice.
Tumor size was measured every 4 days; after 5 weeks,
mice were killed and tumors were dissected out. The
results indicated that the volume of tumors formed by
SGC7901/sh-XIST cells were significantly smaller than
that formed by SGC7901/sh-NC cells, the mean tumor
volume was 313 mm3 and 858 mm3 for the SGC7901/
sh-XIST and SGC7901/sh-NC groups, respectively
(*P < 0.05, Fig. 3c). To further determine the effect
of lncRNA XIST knockdown on tumor metastasis in
vivo, SGC7901/sh-XIST and SGC7901/sh-NC cells
were transplanted into the lateral tail vein of the
nude mice. Six weeks later, mice were killed and
liver metastases were examined. In accordance with
the in vitro results, the number of metastases to the
liver were dramatically reduced in mice injected with
SGC7901/sh-XIST cells compared with those of
SGC7901/sh-NC cells, the mean metastases nodules
were 1.7 and 7.3 for the SGC7901/sh-XIST and SGC7901/
sh-NC groups, respectively (*P < 0.05, Fig. 3d, e and f). In
addition, we performed IHC to determine whether knock-
down of XIST can reduce the expression of Ki-67 and
mmp-9 in tissues taken from tumor growth assay in nude
mice. The results showed that knockdown of XIST
can significantly reduce the level of Ki-67 and mmp-9
(Fig. 3g). These results indicated that knockdown of
Fig. 2 Knockdown of lncRNA XIST expression inhibits gastric cancer cell growth, colony formation, migration and invasion in vitro. a Relative
expression level of lncRNA XIST in different gastric cancer cell lines (*P < 0.05, **P < 0.001). b Real-time PCR confirmed the knockdown of lncRNA
XIST in gastric cancer cell SGC7901 and AGS (*P < 0.05). c and d Knockdown of lncRNA XIST inhibited cell proliferation as indicated by CCK-8
assays in SGC7901 and AGS (One-way ANOVA test, *P < 0.05). e Knockdown of lncRNA XIST inhibited colony formation as demonstrated by colony
formation assays in SGC7901 and AGS (*P < 0.05). f and g Knockdown of lncRNA XIST inhibited cell invasion and migration as indicated by
transwell and wound healing assays (*P < 0.05). h Knockdown of lncRNA XIST increased the level of epithelial markers such as E-cadherin,
α-catenin while reduced the level of mesenchymal markers such as Vimentin and Fibronectin in SGC7901 cells
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Table 1 The correlation between clinicopathological parameters and lncNRA XIST expression levels in 106 gastric cancer patients
Variables n High XIST expression (%) Low XIST expression (%) P value
Age
< 60 74 35(64.8) 39(75.0) 0.253
≥ 60 32 19(35.2) 13(25.0)
Gender
Male 67 33(61.1) 34(65.3) 0.648
Female 39 21(38.9) 18(34.7)
Tumor size
< 5 cm 30 10(18.5) 20(38.4) 0.023a
≥ 5 cm 76 44(81.5) 32(61.6)
Peritoneum dissemination
Absent 89 44(81.4) 45(86.5) 0.478
Present 17 10(18.6) 7(13.5)
Differentiation
Well 19 7(12.9) 12(23.0) 0.326
Moderate 36 18(33.3) 18(34.6)
Poor and others 51 29(43.8) 22(42.4)
Lymph node invasion
Absent 31 10(18.5) 21(40.3) 0.013a
Present 75 44(81.5) 31(59.7)
Distant metastasis
Absent 78 34(62.9) 44(84.6) 0.011a
Present 28 20(37.1) 8(15.4)
TNM stage
I-II 35 12(22.2) 23(44.2) 0.016a
III-IV 71 42(77.8) 29(55.8)
aP < 0.05, Chi-square test
Table 2 Univariate and multivariate analyses of various potential prognostic factors in 106 gastric cancer patients
Factors Univariate analysis Multivariate analysis
HRb(95 % CIc) P HRb(95 % CIc) P
Age 1.11(0.92–1.27) 0.238 - -
Gender 1.25(1.14–1.51) 0.324 - -
Tumor size 1.45(1.13–1.89) 0.097 - -
Peritoneum dissemination 0.99(0.73–1.82) 0.549 - -
Differentiation 1.23(1.11–1.73) 0.095 - -
Lymph node invasion 1.83(1.25–2.22) 0.057 0.93(0.69–1.44) 0.669
Distant metastasis 2.06(1.47–2.98) 0.018a 1.65(1.15–2.56) 0.033a
TNM stage 1.66(1.31–2.15) 0.027a 1.29(1.08–2.36) 0.253
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lncRNA XIST could suppress tumor growth and metastasis
in vivo.
Regulating relationship between lncRNA XIST and miR-101
Increasing evidences showed that lncRNAs can function
as competitive endogenous RNA (ceRNA) for miRNAs
or naturally occurring miRNA sponges. Such ceRNA
networks have identified as critical regulators of gene
expression and signaling pathways. We first used the
bio-informatic tools to search for the potential miRNAs
that can be regulated by lncRNA XIST, to our interest,
miR-101, which has been found to be down-regulated in
gastric cancer, could bind to lncRNA XIST. Fig. 4a
showed the binding sites between lncRNA XIST and
miR-101. We detected the expression of miR-101 in
SGC7901 cells after knockdown of lncRNA XIST, the
result showed that miR-101 level was significantly
increased in SGC7901/sh-XIST cells than that of
SGC7901/sh-NC cells (*P < 0.05, Fig. 4b). Then, we
evaluated whether miR-101 can regulate lncRNA XIST
expression by determine the effects of miR-101 ectopic
expression and inhibition on the expression of lncRNA
Fig. 3 Knockdown of lncRNA XIST expression inhibits tumor growth and metastasis in vivo. a and b The infection efficiency of lentivirus in
SGC7901 cells. Because this vector contains a GFP fragment, the cells emit green fluorescence when infected by the virus. The SGC7901 cells
were observed under light and green fluorescence microscopy (a), real-time PCR analysis confirmed the interference efficiency. c Knockdown of
lncRNA XIST expression significantly inhibited tumor growth of SGC7901 cells, the mean tumor volume was 313 mm3 and 858 mm3 for the
SGC7901/sh-XIST and SGC7901/sh-NC groups, respectively (*P < 0.05). d, e and f Knockdown of lncRNA XIST expression significantly reduced the
metastatic nodules in the liver, the mean metastases nodules were 1.7 and 7.3 for the SGC7901/sh-XIST and SGC7901/sh-NC groups,
respectively (*P < 0.05)
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XIST. As shown in Fig. 4c and d, lncRNA XIST expres-
sion was decreased after ectopic expression of miR-101,
whereas increased after inhibition of miR-101 (*P < 0.05).
To confirm the direct binding relationship between
lncRNA XIST and miR-101, a luciferase activity assay
was conducted. The predicted miR-101 binding site
(XIST-wt) and its mutant type (XIST-mt) were amplified
and directly fused to the downstream of the luciferase
reporter gene in the pmirGLO-basic vector. Co-transfetion
of miR-101 and pmirGLO-XIST-wt significantly de-
creased the luciferase activity, whereas co-transfection
of miR-NC and pmirGLO-XIST-wt did not change the
luciferace activity (*P < 0.05, Fig. 4e). Likewise, cells co-
transfected with miR-101 and pmirGLO-XIST-mt showed
no obvious change in luciferase activity (*P < 0.05, Fig. 4e).
To investigate whether there was inverse correlation
between lncRNA XIST and miR-101 in gastric cancer
tissues, we conducted RT-PCR in 106 gastric tissues to
measure the level of lncRNA XIST and miR-101, a signifi-
cant inverse correlation was found between lncRNA XIST
levels and miR-101 levels in the gastric cancer tissues
(r = −0.6785, P < 0.001, Fig. 4f ). These results demon-
strated that there exist a negative regulation between
lncRNA XIST and miR-101.
lncRNA XIST regulates miR-101 to modulate EZH2 in gas-
tric cancer cells
Having demonstrated that lncRNA XIST can affect miR-
101 expression, we considered the functional aspect. It is
known that miRNAs function by targeting downstream
genes, and EZH2 has been proved to be involved in
gastric cancer progression. Firstly, bioinformatic tools
confirmed the potential miR-101 binding sites in the 3′-
UTR of EZH2 (Fig. 5a). miR-101 was able to markedly
Fig. 4 Regulation relationship between lncRNA XIST and miR-101. a Schematic representation of the predicted target site for miR-101 in lncRNA
XIST. b Knockdown of lncRNA XIST increased miR-101 expression in SGC7901 cells (*P < 0.05). c Real-time PCR analysis confirmed the miR-101
ectopic expression and miR-101 inhibition in SGC7901 cells (*P < 0.05). d Ectopic miR-101 expression decreased lncRNA XIST expression while
inhibition of miR-101 increased lncRNA XIST expression (*P < 0.05). e Luciferase reporter assay in human embryonic kidney (HEK) 293 T cells,
co-transfected with the reporter plasmid (or the corresponding mutant reporter) and the indicated miRNAs. miR-101 significantly decreased the
luciferase activity in XIST-wt but not in XIST-mt (*P < 0.05). f The expression of lncRNA XIST was inversely correlated with the expression level of
miR-101 in gastric cancer tissues (*P < 0.05)
Chen et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:142 Page 9 of 13
reduce the relative luciferase activity of EZH2 3′UTR-wt
in the SGC7901 cells (*P < 0.05), whereas that in the
cells transfected with EZH2 3′UTR-mt was not de-
creased (Fig. 5b). Moreover, the mRNA and protein
levels of EZH2 were significantly decreased by miR-101
ectopic expression in both the SGC7901 cells, and this
reduction could be restored by co-transfected with a
pcDNA3.1-EZH2 vector, which contained the coding
sequences but lacked the 3′-UTR of EZH2 (*P < 0.05,
Fig. 5c and d). Then, we explore whether lncRNA XIST
can modulate the expression of EZH2, to our interest,
we found that knockdown of lncRNA XIST was able to
significantly reduce the mRNA and protein levels of
EZH2, what’s more, knockdown of lncRNA XIST could
reduce the mRNA and protein levels which was in-
creased by miR-101 inhibitor (*P < 0.05, Fig. 5e and f).
In addition, ectopic expression of miR-101 inhibited the
colony formation and invasion ability of SCG7901 cells,
and the suppressive effects could be conteracted by co-
transfected with a pcDNA3.1-EZH2 vector, which con-
tained the coding sequences but lacked the 3′-UTR of
EZH2 (*P < 0.05, Fig. 6a and b). Likewise, knockdown of
lncRNA XIST could suppress the colony formation and
invasion ability stimulated by miR-101 inhibition in
SGC7901 cells (*P < 0.05, Fig. 6c and d). These results
indicated that lncRNA XIST can regulates miR-101 to
modulate EZH2 in gastric cancer cells.
Discussion
Recent studies have indicated that lncRNAs play critical
roles in cancer development and metastasis [28, 29].
Increasing reports revealed that lncRNA expression was
significantly altered in gastric cancer tissue through
screening lncRNA expression profile. For example, Yang
et al. found that lncRNA H19 was up-regulated in tumor
tissues and cells as compared with normal controls, more-
over, forced expression of H19 promoted cell growth [30].
Sun et al. reported that the expression of GAS5 was
significantly down-regulated in gastric cancer, and low
expression of GAS5 was associated with adverse disease-
free survival and overall survival of patients with gastric
cancer. In addition, overexpression of GAS5 could inhibit
gastric cancer cell proliferation and induce apoptosis
both in vitro and in vivo [31]. More recently, Huang et
al. indicated lncRNA KRT7-AS is activated in gastric
cancer and promotes cancer progression by increasing
KRT7 expression [32].
In our study, we found the expression level of lncRNA
XIST was significantly higher in gastric cancer tissues
than that of adjacnet normal tissues. Higher expression
Fig. 5 lncRNA XIST regulates EZH2 expression by acting as a molecular sponge. a The predicted miR-101 binding sites in EZH2 mRNA 3′-UTR as
predicted by Targetscan algorithm. b Luciferase reporter assay for EZH2 mRNA 3′-UTR following miR-101 ectopic expression (*P < 0.05). c and d
EZH2 mRNA and protein level in SGC7901 cells following ectopic expression of miR-101 and/or EZH2 expression vector lacking the 3′-UTR
(*P < 0.05). e and f EZH2 mRNA and protein level in SGC7901 cells following knockdown of lncRNA XIST and/or inhibition of miR-101 (*P < 0.05)
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of lncRNA XIST was positively associated with larger
tumor size, lymph node invasion, distant metastasis and
TNM stage. In addition, overexpression of lncRNA XIST
was associated with adverse prognosis and could be used
as an independent prognostic factor. These results impli-
cated that lncRNA XIST may play an important role in
gastric cancer progression. Consistent with our results,
previous studies have found that lncRNA XIST expres-
sion was up-regulated in patient with collecting duct
carcinoma of the kidney, sporadic human colorectal
cancer, and gastric fundus of a male mouse infected
with helicobacter felis which can lead to gastric can-
cer [33–35]. However, some other studies indicated
that lncRNA XIST was lost in breast, cervical and ovarian
cancer cell lines [36, 37]. These results demonstrated that
lncRNA XIST exhibit remarkably tissue-specific expression
patterns, and it can play oncogenic or tumor-suppressive
role depending on the cancer type and cellular context.
Previous reports have revealed that lncRNA XIST was
essential for long term survival of hematopoietic stem
cells [19], suppression of lncRNA XIST could markedly
impair the early phase of female pluripotent stem cells
induction [38], and knockdown of lncRNA XIST exerts
tumor-suppressive functions in human glioblastoma
stem cells [20]. In our study, we found that knockdown
of lncRNA XIST inhibited cell proliferation, migration
and invasion in vitro. Moreover, in vivo study also
confirmed that knockdown of lncRNA XIST could sup-
press tumor growth and distant metastasis. These results
indicated that dysregulation of lncRNA XIST might be a
common incidence in different tumors.
Mounting reports found that lncRNAs can funtion as
ceRNA for miRNAs, they act as molecular sponges to
competitively inhibit miRNAs. For example, lncRNA
GAS5 can function as a ceRNA for miR-21 [39]; long
non-coding RNA H19 promotes glioma cell invasion by
deriving miR-675 [40]; Long non-coding RNA MEG3
functions as a competing endogenous RNA of miR-181 s
to regulate gastric cancer progression [41]. We specu-
lated that lncRNA XIST might be a ceRNA in gastric
cancer. Using bioinformatics databases (Starbase v2.0,
miRcode and RNAhybrid), we identified 23 miRNAs
which may interact with lncRNA XIST. Further studies
indicated that only miR-101 expression was significantly
increased upon lncRNA XIST knockdown. On the con-
trary, ectopic expression of miR-101 reduced expression
of lncRNA XIST, whereas inhibition of miR-101 inreased
lncRNA XIST expression. These data suggested that an
inverse correlation existed between lncRNA XIST and
miR-101. In addition, a luciferase activity assay con-
firmed the direct binding relationship bwtween lncRNA
XIST and miR-101. A recent study demonstrated that
Fig. 6 EZH2 expression mediated the biological effects exerted by lncRNA XIST. a and b Cell invasion and colony formation assay following
ectopic expression of miR-101 and/or EZH2 expression vector lacking the 3′-UTR (*P < 0.05). c and d Cell invasion and colony formation assay
following knockdown of lncRNA XIST and/or inhibition of miR-101 (*P < 0.05)
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lncRNA XIST fuctions as a ceRNA for miR-152 in
glioma [20]. This implying that lncRNA XIST may inter-
act with different miRNAs in different tumors.
miR-101 has been reported to be down-regulated and
in different tumors [42, 43]. In gastric cancer, previous
studies have demonstrated that down-regulation of miR-
101 resulted in overexpression of EZH2 and promoted
tumor progression [26, 44]. This prompted us to investi-
gate whether knockdown of lncRNA XIST exerted its
tumor-suppressive effects through regulating of EZH2
expression. We first confirmed that miR-101 could nega-
tively regulate EZH2 expression in gastric cancer cells.
Furthermore, knockdown of lncRNA XIST was able to
reduce the mRNA and protein levels of EZH2, what’s
more, knockdown of lncRNA XIST could reduce the
mRNA and protein levels of EZH2 which was increased
by miR-101 inhibitor. In addition, knockdown of lncRNA
XIST could suppress the colony formation and invasion
ability stimulated by miR-101 in gastric cancer cells. These
data revealed that lncRNA XIST exerts its biological
effects at least in part by modulating EZH2 expression.
This is in accordance with our previous results that EZH2
is overexpressed and promotes tumor progression in gas-
tric cancer [45].
Conclusions
In this study, we demonstrated that lncRNA XIST was
significantly overexpressed in gastric cancer tissues and
cell lines. Overexpression of lncRNA XIST was closely
associated with an aggressive tumor phenotype and
adverse prognosis in gastric cancer patients. Knockdown
of lncRNA XIST suppressed cell proliferation, migration
and invasion in vitro and tumorigenesis and metastasis
in vivo. Furthermove, an inverse relationship was found
between lncRNA XIST and miR-101, and knockdown of
lncRNA XIST exerted its tumor-suppressive effects at
least in part through regulating miR-101 to modulate
EZH2 expression. Therefore, we provided the first evi-
dence that knockdown of lncRNA XIST could inhibit
gastric cancer progression and metastasis by modulating
the miR-101/EZH2 pathway.
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